Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- bederní obratle patofyziologie MeSH
- biologické markery krev MeSH
- fosfáty krev MeSH
- inhibitory kostní resorpce aplikace a dávkování terapeutické užití MeSH
- injekce subkutánní MeSH
- izoenzymy krev MeSH
- kolagen typu I krev MeSH
- kostní denzita účinky léků MeSH
- kyselá fosfatasa rezistentní k tartarátu MeSH
- kyselá fosfatasa krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- peptidové fragmenty krev MeSH
- peptidy krev MeSH
- postmenopauzální osteoporóza krev farmakoterapie patofyziologie MeSH
- prokolagen krev MeSH
- rozvrh dávkování léků MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- teriparatid aplikace a dávkování terapeutické užití MeSH
- vápník krev MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- biologické markery MeSH
- collagen type I trimeric cross-linked peptide MeSH Prohlížeč
- fosfáty MeSH
- inhibitory kostní resorpce MeSH
- izoenzymy MeSH
- kolagen typu I MeSH
- kyselá fosfatasa rezistentní k tartarátu MeSH
- kyselá fosfatasa MeSH
- peptidové fragmenty MeSH
- peptidy MeSH
- procollagen Type I N-terminal peptide MeSH Prohlížeč
- prokolagen MeSH
- teriparatid MeSH
- vápník MeSH
UNLABELLED: A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening application. The results indicate that the response of bone cells to teriparatide treatment depends on dosing time. INTRODUCTION: The aim of this study was to assess the long-term effects of the morning vs. the evening teriparatide administration on BMD and bone turnover markers (BTMs) in postmenopausal osteoporosis. METHODS: Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening. The BMD and serum concentrations of C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were measured at baseline, after 6 and 12 months. General linear model-repeated measurements were used to analyze the data. RESULTS: After 12 months, the lumbar spine BMD grew markedly (p < 0.001) with a significantly greater increase in the morning arm compared to the evening arm (9.1% vs. 4.8%, respectively, p < 0.05). The BMD at the distal radius significantly decreased (p < 0.001), with no differences between the arms. The BMD at proximal femur did not change significantly. After 6 months, the BTMs were significantly increased compared with baseline (p < 0.001). The increases in the evening arm vs. the morning arm, however, were more pronounced in PINP (+358% vs. +215%, respectively) and in TRAP 5b (+70% vs. +37%, respectively) (both p < 0.05). CONCLUSION: 12-month morning administration of TPTD resulted in a larger increase in the lumbar spine BMD than the evening application. The timing of TPTD administration may be important for its efficacy.
Zobrazit více v PubMed
J Bone Miner Res. 2005 Jun;20(6):962-70 PubMed
Osteoporos Int. 2011 Jun;22(6):1935-46 PubMed
Osteoporos Int. 1998;8(2):121-6 PubMed
J Clin Endocrinol Metab. 2005 Jul;90(7):3970-7 PubMed
N Engl J Med. 2003 Sep 25;349(13):1207-15 PubMed
J Clin Endocrinol Metab. 2010 Apr;95(4):1838-45 PubMed
Osteoporos Int. 2007 May;18(5):681-5 PubMed
Dan Med Bull. 1994 Apr;41(2):216-27 PubMed
J Bone Miner Res. 2007 Apr;22(4):495-502 PubMed
Metab Bone Dis Relat Res. 1982;4(1):1-6 PubMed
N Engl J Med. 2001 May 10;344(19):1434-41 PubMed
J Bone Miner Res. 2005 Nov;20(11):1905-11 PubMed
J Bone Miner Res. 2003 Jan;18(1):9-17 PubMed
Bone. 2010 Jun;46(6):1486-97 PubMed
Eur J Endocrinol. 2011 Apr;164(4):643-8 PubMed
Rev Endocr Metab Disord. 2006 Jun;7(1-2):113-21 PubMed
J Clin Endocrinol Metab. 1994 Sep;79(3):730-5 PubMed
J Biol Chem. 2010 Sep 3;285(36):28164-73 PubMed
J Clin Endocrinol Metab. 2005 Aug;90(8):4644-9 PubMed
J Bone Miner Res. 2007 Aug;22(8):1173-80 PubMed
Endocrinology. 2002 Oct;143(10):4038-47 PubMed
J Bone Miner Res. 1991 Jul;6(7):759-66 PubMed
J Bone Miner Res. 2003 Nov;18(11):1932-41 PubMed
J Bone Miner Res. 2006 Mar;21(3):366-73 PubMed
Bone. 2007 Jun;40(6):1434-46 PubMed
Bone. 2002 Jul;31(1):57-61 PubMed
J Bone Miner Res. 2008 Oct;23(10):1591-600 PubMed
